Cocaine moves ahead of heroin in England and Wales drug deaths
Cocaine has overtaken heroin as a leading substance linked to drug poisoning deaths in England and Wales, marking a stark change in the profile of fatal overdose across the country. In 2025, cocaine was mentioned in 1,233 deaths, slightly fewer than the year before, yet still above the 1,210 deaths linked to heroin or morphine. The shift is clinically significant because it reflects not only changing drug supply but also changing patterns of use, contamination, and co-use with other high-risk substances.
One sentence captures the scale of the problem: cocaine-related deaths are now roughly four times higher than they were in 2015.
The overall picture is complicated by the fact that the broader category of opiate and opioid deaths remained higher than cocaine alone, and by the usual lag between death occurrence and registration. Even so, cocaine now accounted for more than one in five drug poisoning deaths registered in 2025, more than any other single substance. The figure carries weight well beyond a single drug class. It points to a market in which stimulants and depressants increasingly overlap, with lethal outcomes often driven by polysubstance exposure rather than one isolated agent.
Purity, availability and a more dangerous drug supply
Charities and addiction specialists linked the rise in cocaine deaths to higher purity and wider availability. That matters in practice because a more potent stimulant supply increases the risk of cardiovascular strain, agitation, seizures, hyperthermia and sudden collapse, especially when users do not know the strength of the product they are taking. Cocaine is also used in ways that amplify harm: smoking crack, injecting, or combining it with opioids and counterfeit tablets. Those combinations raise the risk of respiratory depression and overdose in the same person, sometimes within the same episode of use.
Dr James Morgan, who specialises in addiction and mental health at London Metropolitan University, said the slight fall in deaths should not be read as reassurance. Total drug fatalities in England and Wales have roughly doubled since 2012, and the burden remains objectively high. His warning reflects a familiar pattern in overdose epidemiology: short-term fluctuations can mask a sustained upward trajectory in mortality when the underlying supply remains unstable and the same vulnerable communities continue to absorb the greatest harm.
The cocaine figures are especially troubling because they sit at the intersection of stimulant toxicity and opioid contamination. In many deaths, cocaine is not acting alone. It is part of a mixed drug environment in which users may also be exposed to heroin, morphine, fentanyl-like compounds, or other synthetic opioids. That creates a hazardous pharmacological mix: one drug pushes heart rate and blood pressure up while another suppresses respiration. The body loses its ability to compensate, and fatal poisoning can follow quickly.
Ketamine deaths and the changing age of harm
Ketamine also moved sharply in the wrong direction. A record 115 ketamine-linked deaths were registered in 2025, almost twice as many as in 2024 and far above the seven fatalities recorded a decade earlier. The rise is small in absolute terms compared with cocaine or opioid deaths, but the speed of increase is clinically alarming. Ketamine has a different risk profile from heroin or cocaine, yet dependence, injury, and acute toxicity are becoming more visible as use normalises and prices fall.
A single drug can shift from nightclub novelty to public health problem with surprising speed.
Morgan said there were increasing reports of young people becoming dependent on ketamine and suffering bladder damage. That complication is well recognised in clinical practice: repeated use can injure the urinary tract and lead to pain, frequency, urgency, and long-term lower urinary symptoms. For a substance once framed as a recreational dissociative, the emergence of chronic physical harm broadens the concern beyond overdose alone. It also means more patients are likely to present to primary care, emergency departments and urology services with problems that may not be immediately linked to drug use unless clinicians ask directly.
Regional inequality is widening, not shrinking
The national decline in the overall drug death rate should not obscure the geography of harm. The rate of drug poisoning deaths was more than twice as high in the North East as in London, and the steepest increases were seen in former industrial areas with long-standing poverty and unemployment, including the North East, Wales, Yorkshire and the Humber, the North West and the East Midlands. The pattern is not random. It reflects the cumulative effect of deprivation, insecure housing, poor access to treatment, disrupted support networks and an uneven recovery from earlier economic decline.
Those differences are visible in the mortality figures themselves. England and Wales registered 5,519 drug poisoning deaths in 2025, equivalent to 92.4 deaths per million people. That compares with 93.9 deaths per million a year earlier, the first annual decline since 2012. A fall of that size is not enough to counter the broader reality that some regions continue to lose far more people than others. For clinicians and public health teams, the implication is clear: national averages can hide local emergency.
Synthetic opioids are deepening the risk profile
Mike Trace, chief executive of the addiction charity Forward Trust, pointed to the spread of potent synthetic opioids called nitazenes as another reason deaths remain so high. Nitazenes can be many times more potent than heroin and have been linked to hundreds of deaths in the UK. Their arrival changes the overdose equation because they can be present in drugs that users believe are cocaine, heroin, or another familiar substance. If that contamination goes unrecognised, the margin for survival narrows sharply.
The family of Anthony Irvin, who died from drug poisoning in Ramsgate in September 2025 at the age of 52, believes contaminated supply may have played a role. Delays in blood testing mean they may never know with certainty. That uncertainty is itself part of the harm. For bereaved families, a delayed toxicology result can leave the cause of death unresolved and prevent a clearer public understanding of what was in circulation at the time.
In practical terms, the 2025 figures point to a drug market that has become both more potent and more unpredictable. Cocaine is killing more people than heroin in registered deaths. Ketamine deaths are rising quickly. Nitazenes are adding a hidden opioid threat. The data also show that even when overall mortality dips, the burden remains concentrated in the poorest regions and among people exposed to multiple substances at once. The next challenge is not simply counting deaths more accurately, but reducing the toxicity of the supply before the numbers climb again.